CDK2 inhibitor NU6301 Small Molecule (Tool Compound)

CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex, which regulates progression through the cell cycle. Activity of this protein is especially critical during the G1 to S phase transition.

Contributors

Inventor Institute
Roger Griffin Newcastle University
Cat. #: 152754
Tool sub type: Inhibitor
Research Fields: Cancer
Application: The prodrug NU6301 rapidly generated NU6102 in vitro in mouse plasma, and tumour NU6102 levels in vivo consistent with activity in vitro. Eight or 12 hourly dosing of 120 mg/kg NU6301 for 10 days was well tolerated in SKUT-1B tumour-bearing mice and inhibited Rb phosphorylation in tumour tissue. Two (8 hourly dosing) and 3 (12 hourly dosing) day tumour growth delay was observed (p=0.04 and p=0.007, respectively) following NU6301 administration. NU6102 selectively inhibited the growth of CDK2 WT (wild type) versus KO MEFs (knockout mouse embryo fibroblasts) (GI₅₀ (concentration required to inhibit cell growth by 50%) 14 μM versus >30 μM), and was more growth-inhibitory in p53 mutant or null versus p53 WT cells (p=0.02), and in Rb (retinoblastoma protein) WT SKUT-1B versus SKUT 1 Rb deficient cells (p=0.01). In SKUT-1B cells NU6102 induced a G2 arrest, inhibition of Rb phosphorylation and cytotoxicity (LC₅₀ 2.6 μM for a 24h exposure).
Purpose: Inhibitor
Product description: The CDK2 inhibitor NU6301 is a water soluble prodrug of NU6102, a potent CDK1/cyclin B and CDK2/cyclin A3 inhibitor (IC50 values are 9.5 and 5.4 nM for CDK1/cyclin B and CDK2/cyclin A3 respectively). CDK2 is a member of a family of serine/threonine protein kinases that participate in cell cycle regulation. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex, which regulates progression through the cell cycle. Activity of this protein is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).
Primary target: Cyclin dependent kinase 2 (CDK2)
Shipping conditions: Dry Ice
References:

Thomas, H et al

European Journal of Cancer, Volume 47, Issue 13, September 2011, Pages 2052–2059

Related Tools for Small molecules

Cat. # Tool Name
151832 LIMK inhibitor CRT0105950 Small Molecule (Tool Compound) Key Info View Tool
151839 Antitumoral Phortress Small Molecule (Tool Compound) Key Info View Tool
151840 Antitumoral Quinol2 Small Molecule (Tool Compound) Key Info View Tool
151880 AKR1C3 inhibitor CRT0093964 Small Molecule (Tool Compound) Key Info View Tool
153334 HDAC3:SMRT Fluorescent Probe 2-FAM-InsP5 Small Molecule (Tool Compound) Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.